In a phase-3 study, 676 unresectable stage III or IV melanoma patients received either a vaccine containing two gp100 peptides corresponding to antigens expressed by melanoma and normal melanocytes, or Ipilimumab alone, or Ipilimumab plus the gp100 vaccine [166]. The gene discussed is PMEL; the disease is melanoma.